License Revenue (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
License Agreement Terms [Member]
Gross up-front license fee	$ 6.0
Aggregate licence payment received		$ 14.0
Description of licensing agreement	The Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.
Revenue recognized performance obligation description of payment	Over the performance period through March 2023 (the “Performance Period”), the expected period over which the Company conservatively expects the Services to be performed with approval in the Territory expected by the end of March 2023.
License revenue	$ 0.5
Up-front Payment Arrangement [Member]
Upfront payment	$ 4.5